BACKGROUND: Elevated uptake of the [18 F]AV-1451 tau-PET ligand has been observed cross-sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [18 F]AV-1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy. METHODS: Sixteen subjects with PSP underwent 2 serial [18 F]AV-1451 tau-PET scans and 3-Tesla MRI over 12 months and were age- and sex-matched to 39 healthy controls with longitudinal [18 F]AV-1451 PET. Median [18 F]AV-1451 uptake was calculated for each scan for regions of interest across the brain and divided by uptake in cerebellar crus to create standard uptake value ratios. Midbrain volume on MRI was also calculated for each scan. Sample sizes required to power placebo-controlled treatment trials were calculated. RESULTS: Rate of midbrain atrophy was significantly increased in PSP compared with controls. [18 F]AV-1451 regional change measures were significantly increased in PSP compared with controls in the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain. Change over time in the PSP Rating Scale correlated with change in midbrain volume but did not correlate with change in the [18 F]AV-1451 measures. Smallest sample-size estimates were obtained with rate of midbrain atrophy, followed by the PSP Rating Scale, with both outperforming [18 F]AV-1451 measures. CONCLUSIONS: [18 F]AV-1451 tau-PET measures increase over time in subjects with PSP, but longitudinal [18 F]AV-1451 measures may not perform as well as rate of midbrain atrophy as biomarkers for PSP clinical trials.
BACKGROUND: Elevated uptake of the [18 F]AV-1451tau-PET ligand has been observed cross-sectionally in subjects with progressive supranuclear palsy (PSP). However, it is unknown how the ligand performs longitudinally in PSP. We aimed to determine how regional measures of change on [18 F]AV-1451 PET perform as longitudinal biomarkers of PSP compared with the more established biomarker of rate of midbrain atrophy. METHODS: Sixteen subjects with PSP underwent 2 serial [18 F]AV-1451tau-PET scans and 3-Tesla MRI over 12 months and were age- and sex-matched to 39 healthy controls with longitudinal [18 F]AV-1451 PET. Median [18 F]AV-1451 uptake was calculated for each scan for regions of interest across the brain and divided by uptake in cerebellar crus to create standard uptake value ratios. Midbrain volume on MRI was also calculated for each scan. Sample sizes required to power placebo-controlled treatment trials were calculated. RESULTS: Rate of midbrain atrophy was significantly increased in PSP compared with controls. [18 F]AV-1451 regional change measures were significantly increased in PSP compared with controls in the pallidum, precentral cortex, dentate nucleus of the cerebellum, and midbrain. Change over time in the PSP Rating Scale correlated with change in midbrain volume but did not correlate with change in the [18 F]AV-1451 measures. Smallest sample-size estimates were obtained with rate of midbrain atrophy, followed by the PSP Rating Scale, with both outperforming [18 F]AV-1451 measures. CONCLUSIONS: [18 F]AV-1451tau-PET measures increase over time in subjects with PSP, but longitudinal [18 F]AV-1451 measures may not perform as well as rate of midbrain atrophy as biomarkers for PSP clinical trials.
Authors: Yasushi Osaki; Yoav Ben-Shlomo; Andrew J Lees; Susan E Daniel; Carlo Colosimo; Gregor Wenning; Niall Quinn Journal: Mov Disord Date: 2004-02 Impact factor: 10.338
Authors: Jennifer L Whitwell; Ramesh Avula; Ankit Master; Prashanthi Vemuri; Matthew L Senjem; David T Jones; Clifford R Jack; Keith A Josephs Journal: Parkinsonism Relat Disord Date: 2011-06-12 Impact factor: 4.891
Authors: Jennifer L Whitwell; Jia Xu; Jay Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs Journal: Mov Disord Date: 2012-03-13 Impact factor: 10.338
Authors: Marta Marquié; Marc D Normandin; Charles R Vanderburg; Isabel M Costantino; Elizabeth A Bien; Lisa G Rycyna; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik L Debnath; Neil Vasdev; Bradford C Dickerson; Stephen N Gomperts; John H Growdon; Keith A Johnson; Matthew P Frosch; Bradley T Hyman; Teresa Gómez-Isla Journal: Ann Neurol Date: 2015-09-25 Impact factor: 10.422
Authors: Shubir Dutt; Richard J Binney; Hilary W Heuer; Phi Luong; Suneth Attygalle; Priyanka Bhatt; Gabe A Marx; Jonathan Elofson; Maria C Tartaglia; Irene Litvan; Scott M McGinnis; Bradford C Dickerson; John Kornak; Dana Waltzman; Lisa Voltarelli; Norbert Schuff; Gil D Rabinovici; Joel H Kramer; Clifford R Jack; Bruce L Miller; Howard J Rosen; Adam L Boxer Journal: Neurology Date: 2016-10-14 Impact factor: 9.910
Authors: Irene Sintini; Christopher G Schwarz; Matthew L Senjem; Robert I Reid; Hugo Botha; Farwa Ali; J Eric Ahlskog; Clifford R Jack; Val J Lowe; Keith A Josephs; Jennifer L Whitwell Journal: Parkinsonism Relat Disord Date: 2019-07-02 Impact factor: 4.891
Authors: Sabrina Katzdobler; Alexander Nitschmann; Johannes Levin; Matthias Brendel; Henryk Barthel; Gerard Bischof; Leonie Beyer; Ken Marek; Mengmeng Song; Olivia Wagemann; Carla Palleis; Endy Weidinger; Anne Nack; Urban Fietzek; Carolin Kurz; Jan Häckert; Theresa Stapf; Christian Ferschmann; Maximilian Scheifele; Florian Eckenweber; Gloria Biechele; Nicolai Franzmeier; Anna Dewenter; Sonja Schönecker; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Andrew W Stephens; Thilo van Eimeren; Bernd Neumaier; Alexander Drzezga; Adrian Danek; Joseph Classen; Katharina Bürger; Daniel Janowitz; Boris-Stephan Rauchmann; Sophia Stöcklein; Robert Perneczky; Florian Schöberl; Andreas Zwergal; Günter U Höglinger; Peter Bartenstein; Victor Villemagne; John Seibyl; Osama Sabri Journal: Eur J Nucl Med Mol Imaging Date: 2022-09-14 Impact factor: 10.057
Authors: Rene L Utianski; Peter R Martin; Hugo Botha; Christopher G Schwarz; Joseph R Duffy; Ronald C Petersen; David S Knopman; Heather M Clark; Alissa M Butts; Mary M Machulda; Clifford R Jack; Val J Lowe; Jennifer L Whitwell; Keith A Josephs Journal: Cortex Date: 2019-11-19 Impact factor: 4.027
Authors: Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger Journal: Nat Rev Neurol Date: 2021-08-23 Impact factor: 42.937
Authors: Heather M Clark; Nirubol Tosakulwong; Stephen D Weigand; Farwa Ali; Hugo Botha; Nha Trang Thu Pham; Christopher G Schwarz; Robert I Reid; Matthew L Senjem; Clifford R Jack; Val J Lowe; J Eric Ahlskog; Keith A Josephs; Jennifer L Whitwell Journal: Mov Disord Date: 2021-08-23 Impact factor: 10.338
Authors: Matthias Brendel; Henryk Barthel; Thilo van Eimeren; Ken Marek; Leonie Beyer; Mengmeng Song; Carla Palleis; Mona Gehmeyr; Urban Fietzek; Gesine Respondek; Julia Sauerbeck; Alexander Nitschmann; Christian Zach; Jochen Hammes; Michael T Barbe; Oezguer Onur; Frank Jessen; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Bernd Neumaier; Olivier Barret; Jennifer Madonia; David S Russell; Andrew Stephens; Sigrun Roeber; Jochen Herms; Kai Bötzel; Joseph Classen; Peter Bartenstein; Victor Villemagne; Johannes Levin; Günter U Höglinger; Alexander Drzezga; John Seibyl; Osama Sabri Journal: JAMA Neurol Date: 2020-11-01 Impact factor: 18.302
Authors: Sanne Simone Kaalund; Luca Passamonti; Kieren S J Allinson; Alexander G Murley; Trevor W Robbins; Maria Grazia Spillantini; James B Rowe Journal: Acta Neuropathol Commun Date: 2020-02-04 Impact factor: 7.801
Authors: Alexander G Murley; Ian Coyle-Gilchrist; Matthew A Rouse; P Simon Jones; Win Li; Julie Wiggins; Claire Lansdall; Patricia Vázquez Rodríguez; Alicia Wilcox; Kamen A Tsvetanov; Karalyn Patterson; Matthew A Lambon Ralph; James B Rowe Journal: Brain Date: 2020-05-01 Impact factor: 15.255